Brief: Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers
25/11/2025 11:55
Nov 25 (Reuters) - Personalis Inc PSNL.O: PERSONALIS INC - CMS REVISES REIMBURSEMENT RATE FOR NEXT PERSONAL TEST FOR POST-TREATMENT SURVEILLANCE OF CANCER - SEC FILING PERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILING Source text: [ID:n0001193125-25-294454] Further company coverage: PSNL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary